Skip to content
2000
image of Neuroprotective Marine Bioactives in Paediatric ADHD: A Focused Review on Therapeutic Potential

Abstract

Introduction

Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental condition in children, marked by symptoms of inattention, hyperactivity, and impulsivity. This review examines the potential of marine-derived bioactive compounds as promising alternatives to support neurodevelopment and aid in managing ADHD-related symptoms.

Methods

Databases such as PubMed, Scopus, Web of Science, and ClinicalTrials.gov were searched using terms related to marine bioactives and ADHD. Studies published up to July 2025 were considered, focusing on human clinical trials and preclinical research involving children or outcomes related to neurodevelopment. Reviews focusing on marine-based sources have increasingly highlighted their potential in enhancing cognitive function, attention regulation, and overall neurodevelopment in children with ADHD. This review offers a targeted analysis of marine-derived compounds with potential therapeutic value in the management of ADHD in children.

Results

Marine sources offer several neuroprotective agents, including Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA), which are critical for brain development, especially in children. Compounds such as Klamin®, derived from , contain beta-phenylethylamine and phycocyanins that exhibit monoamine oxidase B inhibition and may support attention regulation. Bioactive peptides and marine polysaccharides also demonstrate significant anti-inflammatory and neuroregenerative potential.

Discussion

Marine bioactives represent a unique and largely untapped avenue for ADHD management through nutritional and functional interventions. Compared to conventional pharmacological treatments, these compounds offer natural, potentially safer options. However, clinical studies are limited, and further research is needed to establish efficacy, optimal dosing, and long-term safety.

Conclusion

Marine-derived compounds exhibit promising neuroprotective and cognitive-enhancing properties relevant to the management of ADHD. Future research and clinical validation may pave the way for integrating these natural agents into therapeutic and dietary strategies for children with ADHD.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/0118715273418458251114104948
2026-02-23
2026-03-02

  • From This Site

    /content/journals/cnsnddt/10.2174/0118715273418458251114104948
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Hinshaw S.P. Arnold L.E. ADHD, multimodal treatment, and longitudinal outcome: Evidence, paradox, and challenge. Wiley Interdiscip. Rev. Cogn. Sci. 2015 6 1 39 52 10.1002/wcs.1324 25558298
    [Google Scholar]
  2. Hassan S.S. Samanta S. Dash R. Karpiński T.M. Habibi E. Sadiq A. Ahmadi A. Bungau S. The neuroprotective effects of fisetin, a natural flavonoid in neurodegenerative diseases: Focus on the role of oxidative stress. Front. Pharmacol. 2022 13 1015835 10.3389/fphar.2022.1015835 36299900
    [Google Scholar]
  3. Hassan S.S. Abdel-Daim M.M. Behl T. Bungau S. Natural products for chronic diseases: A ray of hope. Molecules 2022 27 17 5573 10.3390/molecules27175573 36080344
    [Google Scholar]
  4. Ahn J. Ahn H.S. Cheong J.H. dela Peña I. Natural product-derived treatments for attention-deficit/hyperactivity disorder: Safety, efficacy, and therapeutic potential of combination therapy. Neural Plast. 2016 2016 1 18 10.1155/2016/1320423 26966583
    [Google Scholar]
  5. Bozinovic K. McLamb F. O’Connell K. Olander N. Feng Z. Haagensen S. Bozinovic G. U.S. national, regional, and state-specific socioeconomic factors correlate with child and adolescent ADHD diagnoses pre-COVID-19 pandemic. Sci. Rep. 2021 11 1 22008 10.1038/s41598‑021‑01233‑2 34759326
    [Google Scholar]
  6. Ayano G. Demelash S. Gizachew Y. Tsegay L. Alati R. The global prevalence of attention deficit hyperactivity disorder in children and adolescents: An umbrella review of meta-analyses. J. Affect. Disord. 2023 339 860 866 10.1016/j.jad.2023.07.071 37495084
    [Google Scholar]
  7. Morrow C.E. Accornero V.H. Xue L. Manjunath S. Culbertson J.L. Anthony J.C. Bandstra E.S. Estimated risk of developing selected DSM-IV disorders among 5-year-old children with prenatal cocaine exposure. J. Child Fam. Stud. 2009 18 3 356 364 10.1007/s10826‑008‑9238‑6 27761099
    [Google Scholar]
  8. Millichap J.G. Etiologic classification of attention-deficit/hyperactivity disorder. Pediatrics 2008 121 2 e358 e365 10.1542/peds.2007‑1332 18245408
    [Google Scholar]
  9. del Campo N. Chamberlain S.R. Sahakian B.J. Robbins T.W. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol. Psychiatry 2011 69 12 e145 e157 10.1016/j.biopsych.2011.02.036 21550021
    [Google Scholar]
  10. Salvi V. Migliarese G. Venturi V. Rossi F. Torriero S. Viganò V. Cerveri G. Mencacci C. ADHD in adults: Clinical subtypes and associated characteristics. Riv. Psichiatr. 2019 54 2 84 89 10.1708/3142.31249 30985833
    [Google Scholar]
  11. Alasavar C. Shahidi F. Miyashita K. Wanasundara U. Handbook of seafood quality, safety, and health applications. Chichester 2011 10.1002/9781444325546
    [Google Scholar]
  12. Shahidi F. Janak Kamil Y.V.A. Enzymes from fish and aquatic invertebrates and their application in the food industry. Trends Food Sci. Technol. 2001 12 12 435 464 10.1016/S0924‑2244(02)00021‑3
    [Google Scholar]
  13. Ngo D.H. Vo T.S. Ngo D.N. Wijesekara I. Kim S.K. Biological activities and potential health benefits of bioactive peptides derived from marine organisms. Int. J. Biol. Macromol. 2012 51 4 378 383 10.1016/j.ijbiomac.2012.06.001 22683669
    [Google Scholar]
  14. McLennan J.D. Understanding attention deficit hyperactivity disorder as a continuum. Can. Fam. Physician 2016 62 12 979 982 27965331
    [Google Scholar]
  15. Iriti M. Vitalini S. Fico G. Faoro F. Neuroprotective herbs and foods from different traditional medicines and diets. Molecules 2010 15 5 3517 3555 10.3390/molecules15053517 20657497
    [Google Scholar]
  16. Burdge G.C. Calder P.C. Dietary α-linolenic acid and health-related outcomes: a metabolic perspective. Nutr. Res. Rev. 2006 19 1 26 52 10.1079/NRR2005113 19079874
    [Google Scholar]
  17. Faraone S.V. Mick E. Molecular genetics of attention deficit hyperactivity disorder. Psychiatr. Clin. North Am. 2010 33 1 159 180 10.1016/j.psc.2009.12.004 20159345
    [Google Scholar]
  18. Gibson R.A. Neumann M.A. Makrides M. Effect of increasing breast milk docosahexaenoic acid on plasma and erythrocyte phospholipid fatty acids and neural indices of exclusively breast fed infants. Eur. J. Clin. Nutr. 1997 51 9 578 584 10.1038/sj.ejcn.1600446 9306083
    [Google Scholar]
  19. Anderson G.J. Neuringer M. Lin D.S. Connor W.E. Can prenatal N-3 fatty acid deficiency be completely reversed after birth? Effects on retinal and brain biochemistry and visual function in rhesus monkeys. Pediatr. Res. 2005 58 5 865 872 10.1203/01.pdr.0000182188.31596.5a 16257925
    [Google Scholar]
  20. Youdim K.A. Martin A. Joseph J.A. Essential fatty acids and the brain: possible health implications. Int. J. Dev. Neurosci. 2000 18 4-5 383 399 10.1016/S0736‑5748(00)00013‑7 10817922
    [Google Scholar]
  21. Fields R.D. Araque A. Johansen-Berg H. Lim S.S. Lynch G. Nave K.A. Nedergaard M. Perez R. Sejnowski T. Wake H. Glial biology in learning and cognition. Neuroscientist 2014 20 5 426 431 10.1177/1073858413504465 24122821
    [Google Scholar]
  22. Bowen R.A.R. Clandinin M.T. Maternal dietary 22: 6 n -3 is more effective than 18: 3 n -3 in increasing the 22: 6 n -3 content in phospholipids of glial cells from neonatal rat brain. Br. J. Nutr. 2005 93 5 601 611 10.1079/BJN20041390 15975158
    [Google Scholar]
  23. Blank C. Neumann M.A. Makrides M. Gibson R.A. Optimizing DHA levels in piglets by lowering the linoleic acid to α-linolenic acid ratio. J. Lipid Res. 2002 43 9 1537 1543 10.1194/jlr.M200152‑JLR200 12235186
    [Google Scholar]
  24. Menkes J.H. Early feeding history of children with learning disorders. Dev. Med. Child Neurol. 1977 19 2 169 171 10.1111/j.1469‑8749.1977.tb07966.x 858447
    [Google Scholar]
  25. Rodgers B. Feeding in infancy and later ability and attainment: A longitudinal study. Dev. Med. Child Neurol. 1978 20 4 421 426 10.1111/j.1469‑8749.1978.tb15242.x 689307
    [Google Scholar]
  26. Taylor B. Wadsworth J. Breast feeding and child development at five years. Dev. Med. Child Neurol. 1984 26 1 73 80 10.1111/j.1469‑8749.1984.tb04409.x 6698329
    [Google Scholar]
  27. Al M.D. Badart-Smook A. von Houwelingen A.C. Hasaart T.H. Hornstra G. Fat intake of women during normal pregnancy: Relationship with maternal and neonatal essential fatty acid status. J. Am. Coll. Nutr. 1996 15 1 49 55 10.1080/07315724.1996.10718564 8632115
    [Google Scholar]
  28. Hornstra G. Essential fatty acids in mothers and their neonates. Am. J. Clin. Nutr. 2000 71 Suppl 5 1262S 1269S 10.1093/ajcn/71.5.1262s 10799400
    [Google Scholar]
  29. Foreman-van Drongelen M.M. Zeijdner E.E. van Houwelingen A.C. Kester A.D. Al M.D. Hasaart T.H. Hornstra G. Essential fatty acid status measured in umbilical vessel walls of infants born after a multiple pregnancy. Early Hum. Dev. 1996 46 3 205 215 10.1016/0378‑3782(96)01745‑8 8922565
    [Google Scholar]
  30. Zeijdner E.E. Houwelingen A.C. Kester A.D.M. Hornstra G. Essential fatty acid status in plasma phospholipids of mother and neonate after multiple pregnancy. Prostaglandins Leukot. Essent. Fatty Acids 1997 56 5 395 401 10.1016/S0952‑3278(97)90590‑1 9175178
    [Google Scholar]
  31. Sugano M. Ikeda I. Metabolic interactions between essential and trans-fatty acids. Curr. Opin. Lipidol. 1996 7 1 38 42 10.1097/00041433‑199602000‑00009 8925188
    [Google Scholar]
  32. Carlson S.E. Werkman S.H. Peeples J.M. Wilson W.M. Long-chain fatty acids and early visual and cognitive development of preterm infants. Eur. J. Clin. Nutr. 1994 48 S27 S30 7995262
    [Google Scholar]
  33. Carlson S.E. Werkman S.H. A randomized trial of visual attention of preterm infants fed docosahexaenoic acid until two months. Lipids 1996 31 1Part1 85 90 10.1007/BF02522416 8649239
    [Google Scholar]
  34. Werkman S.H. Carlson S.E. A randomized trial of visual attention of preterm infants fed docosahexaenoic acid until nine months. Lipids 1996 31 1Part1 91 97 10.1007/BF02522417 8649241
    [Google Scholar]
  35. Willatts P. Forsyth J.S. DiModugno M.K. Varma S. Colvin M. Effect of long-chain polyunsaturated fatty acids in infant formula on problem solving at 10 months of age. Lancet 1998 352 9129 688 691 10.1016/S0140‑6736(97)11374‑5 9728984
    [Google Scholar]
  36. Lucas A. Morley R. Cole T.J. Lister G. Leeson-Payne C. Breast milk and subsequent intelligence quotient in children born preterm. Lancet 1992 339 8788 261 264 10.1016/0140‑6736(92)91329‑7 1346280
    [Google Scholar]
  37. Rogan W.J. Gladen B.C. Breast-feeding and cognitive development. Early Hum. Dev. 1993 31 3 181 193 10.1016/0378‑3782(93)90194‑Y 8444137
    [Google Scholar]
  38. Horwood L.J. Fergusson D.M. Breastfeeding and later cognitive and academic outcomes. Pediatrics 1998 101 1 e9 10.1542/peds.101.1.e9 9417173
    [Google Scholar]
  39. Lanting C.I. Huisman M. Boersma E.R. Touwen B.C.L. Fidler V. Neurological differences between 9-year-old children fed breast-milk or formula-milk as babies. Lancet 1994 344 8933 1319 1322 10.1016/S0140‑6736(94)90692‑0 7968027
    [Google Scholar]
  40. Agostoni C. Trojan S. Bellù R. Riva E. Giovannini M. Neurodevelopmental quotient of healthy term infants at 4 months and feeding practice: The role of long-chain polyunsaturated fatty acids. Pediatr. Res. 1995 38 2 262 266 10.1203/00006450‑199508000‑00021 7478826
    [Google Scholar]
  41. Agostoni C. Riva E. Trojan S. Bellù R. Giovannini M. Docosahexaenoic acid status and developmental quotient of healthy term infants. Lancet 1995 346 8975 638 10.1016/S0140‑6736(95)91469‑2 7651024
    [Google Scholar]
  42. Agostoni C. Trojan S. Bellù R. Riva E. Bruzzese M.G. Giovannini M. Developmental quotient at 24 months and fatty acid composition of diet in early infancy: A follow up study. Arch. Dis. Child. 1997 76 5 421 424 10.1136/adc.76.5.421 9196357
    [Google Scholar]
  43. Birch E. Birch D. Hoffman D. Hale L. Everett M. Uauy R. Breast-feeding and optimal visual development. J. Pediatr. Ophthalmol. Strabismus 1993 30 1 33 38 10.3928/0191‑3913‑19930101‑09 8455123
    [Google Scholar]
  44. Carlson S.E. Werkman S.H. Tolley E.A. Effect of long-chain n-3 fatty acid supplementation on visual acuity and growth of preterm infants with and without bronchopulmonary dysplasia. Am. J. Clin. Nutr. 1996 63 5 687 697 10.1093/ajcn/63.5.687 8615350
    [Google Scholar]
  45. Carlson S.E. Werkman S.H. Rhodes P.G. Tolley E.A. Visual-acuity development in healthy preterm infants: effect of marine-oil supplementation. Am. J. Clin. Nutr. 1993 58 1 35 42 10.1093/ajcn/58.1.35 8317386
    [Google Scholar]
  46. Makrides M. Neumann M. Simmer K. Gibson R. Pater J. Are long-chain polyunsaturated fatty acids essential nutrients in infancy? Lancet 1995 345 8963 1463 1468 10.1016/S0140‑6736(95)91035‑2 7769900
    [Google Scholar]
  47. Birch E.E. Hoffman D.R. Uauy R. Birch D.G. Prestidge C. Visual acuity and the essentiality of docosahexaenoic acid and arachidonic acid in the diet of term infants. Pediatr. Res. 1998 44 2 201 209 10.1203/00006450‑199808000‑00011 9702915
    [Google Scholar]
  48. Innis S.M. Akrabawi S.S. Diersen-Schade D.A. Dobson M.V. Guy D.G. Visual acuity and blood lipids in term infants fed human milk or formulae. Lipids 1997 32 1 63 72 10.1007/s11745‑997‑0010‑7 9075195
    [Google Scholar]
  49. Auestad N. Montalto M.B. Hall R.T. Fitzgerald K.M. Wheller R.E. Connor W.E. Neuringer M. Connor S.L. Taylor J.A. Hartmann E.E. Visual acuity, erythrocyte fatty acid composition, and growth in term infants fed formulas with long chain polyunsaturated fatty acids for one year. Ross Pediatric Lipid Study. Pediatr. Res. 1997 41 1 1 10 10.1203/00006450‑199701000‑00001 8979282
    [Google Scholar]
  50. Innis S.M. Nelson C.M. Rioux M.F. King D.J. Development of visual acuity in relation to plasma and erythrocyte ω-6 and ω-3 fatty acids in healthy term gestation infants. Am. J. Clin. Nutr. 1994 60 3 347 352 10.1093/ajcn/60.3.347 8074064
    [Google Scholar]
  51. Innis S.M. Nelson C.M. Lwanga D. Rioux F.M. Waslen P. Feeding formula without arachidonic acid and docosahexaenoic acid has no effect on preferential looking acuity or recognition memory in healthy full-term infants at 9 mo of age. Am. J. Clin. Nutr. 1996 64 1 40 46 10.1093/ajcn/64.1.40 8669412
    [Google Scholar]
  52. Hørby Jørgensen M. Hernell O. Lund P. Hølmer G. Fleischer Michaelsen K. Visual acuity and erythrocyte docosahexaenoic acid status in breast‐fed and formula‐fed term infants during the first four months of life. Lipids 1996 31 1Part1 99 105 10.1007/BF02522418 8649242
    [Google Scholar]
  53. Pangestuti R. Kim S.K. Neuroprotective properties of chitosan and its derivatives. Mar. Drugs 2010 8 7 2117 2128 10.3390/md8072117 20714426
    [Google Scholar]
  54. Ehrenreich H. Sirén A.L. Neuroprotection - What does it mean? - What means do we have? Eur. Arch. Psychiatry Clin. Neurosci. 2001 251 4 149 151 10.1007/s004060170034 11697578
    [Google Scholar]
  55. Kietzmann T. Knabe W. Schmidt-Kastner R. Hypoxia and hypoxia-inducible factor modulated gene expression in brain: involvement in neuroprotection and cell death. Eur. Arch. Psychiatry Clin. Neurosci. 2001 251 4 170 178 10.1007/s004060170037 11697581
    [Google Scholar]
  56. Eftekharzadeh B. Khodagholi F. Abdi A. Maghsoudi N. Alginate protects NT2 neurons against H2O2-induced neurotoxicity. Carbohydr. Polym. 2010 79 4 1063 1072 10.1016/j.carbpol.2009.10.040
    [Google Scholar]
  57. Schwartz G. Fehlings M.G. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: Improved behavioral and neuroanatomical recovery with riluzole. J. Neurosurg. Spine 2001 94 2 245 256 10.3171/spi.2001.94.2.0245 11302627
    [Google Scholar]
  58. Behl C. Moosmann B. Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic approach2 2This article is part of a series of reviews on “Causes and Consequences of Oxidative Stress in Alzheimer’s Disease.” The full list of papers may be found on the homepage of the journal. Free Radic. Biol. Med. 2002 33 2 182 191 10.1016/S0891‑5849(02)00883‑3 12106814
    [Google Scholar]
  59. Woo M.S. Park J.S. Choi I.Y. Kim W.K. Kim H.S. Inhibition of MMP‐3 or ‐9 suppresses lipopolysaccharide‐induced expression of proinflammatory cytokines and iNOS in microglia. J. Neurochem. 2008 106 2 770 780 10.1111/j.1471‑4159.2008.05430.x 18419763
    [Google Scholar]
  60. Gao H.M. Liu B. Zhang W. Hong J.S. Novel anti-inflammatory therapy for Parkinson’s disease. Trends Pharmacol. Sci. 2003 24 8 395 401 10.1016/S0165‑6147(03)00176‑7 12915048
    [Google Scholar]
  61. Luo D. Zhang Q. Wang H. Cui Y. Sun Z. Yang J. Zheng Y. Jia J. Yu F. Wang X. Wang X. Fucoidan protects against dopaminergic neuron death in vivo and in vitro. Eur. J. Pharmacol. 2009 617 1-3 33 40 10.1016/j.ejphar.2009.06.015 19545563
    [Google Scholar]
  62. Barnham K.J. Masters C.L. Bush A.I. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 2004 3 3 205 214 10.1038/nrd1330 15031734
    [Google Scholar]
  63. Akyol Ö. Herken H. Uz E. Fadıllıoǧlu E. Ünal S. Söǧüt S. Özyurt H. Savaş H.A. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002 26 5 995 1005 10.1016/S0278‑5846(02)00220‑8 12369276
    [Google Scholar]
  64. Moosmann B. Behl C. Antioxidants as treatment for neurodegenerative disorders. Expert Opin. Investig. Drugs 2002 11 10 1407 1435 10.1517/13543784.11.10.1407 12387703
    [Google Scholar]
  65. Block M.L. Zecca L. Hong J.S. Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007 8 1 57 69 10.1038/nrn2038 17180163
    [Google Scholar]
  66. Allen N.J. Barres B.A. Glia — More than just brain glue. Nature 2009 457 7230 675 677 10.1038/457675a 19194443
    [Google Scholar]
  67. Kim S.U. de Vellis J. Microglia in health and disease. J. Neurosci. Res. 2005 81 3 302 313 10.1002/jnr.20562 15954124
    [Google Scholar]
  68. Lull M.E. Block M.L. Microglial activation and chronic neurodegeneration. Neurotherapeutics 2010 7 4 354 365 10.1016/j.nurt.2010.05.014 20880500
    [Google Scholar]
  69. Mattson M.P. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 2000 1 2 120 130 10.1038/35040009 11253364
    [Google Scholar]
  70. Yuan J. Yankner B.A. Apoptosis in the nervous system. Nature 2000 407 6805 802 809 10.1038/35037739 11048732
    [Google Scholar]
  71. Patockaa J. Stredab L. Brief review of natural nonprotein neurotoxins. ASA Newsl. 2002 89 16 24
    [Google Scholar]
  72. Segura-Aguilar J. Kostrzewa R.M. Neurotoxins and neurotoxic species implicated in neurodegeneration. Neurotox. Res. 2004 6 7-8 615 630 10.1007/BF03033456 15639792
    [Google Scholar]
  73. Allan Butterfield D. Amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity: Implications for neurodegeneration in Alzheimer’s disease brain. A review. Free Radic. Res. 2002 36 12 1307 1313 10.1080/1071576021000049890 12607822
    [Google Scholar]
  74. Kidd P.M. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Altern. Med. Rev. 2007 12 3 207 227 18072818
    [Google Scholar]
  75. Hirayama S. Hamazaki T. Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder — A placebo-controlled double-blind study. Eur. J. Clin. Nutr. 2004 58 3 467 473 10.1038/sj.ejcn.1601830 14985685
    [Google Scholar]
  76. Stevens L. Zhang W. Peck L. Kuczek T. Grevstad N. Mahon A. Zentall S.S. Eugene Arnold L. Burgess J.R. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003 38 10 1007 1021 10.1007/s11745‑006‑1155‑0 14669965
    [Google Scholar]
  77. Johnson M. Östlund S. Fransson G. Kadesjö B. Gillberg C. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: A randomized placebo-controlled trial in children and adolescents. J. Atten. Disord. 2009 12 5 394 401 10.1177/1087054708316261 18448859
    [Google Scholar]
  78. Richardson A.J. Burton J.R. Sewell R.P. Spreckelsen T.F. Montgomery P. Docosahexaenoic acid for reading, cognition and behavior in children aged 7-9 years: A randomized, controlled trial (the DOLAB Study). PLoS One 2012 7 9 e43909 10.1371/journal.pone.0043909 22970149
    [Google Scholar]
  79. Vaisman N. Kaysar N. Zaruk-Adasha Y. Pelled D. Brichon G. Zwingelstein G. Bodennec J. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: Effect of dietary n−3 fatty acids containing phospholipids. Am. J. Clin. Nutr. 2008 87 5 1170 1180 10.1093/ajcn/87.5.1170 18469236
    [Google Scholar]
  80. Manor I. Magen A. Keidar D. Rosen S. Tasker H. Cohen T. Richter Y. Zaaroor-Regev D. Manor Y. Weizman A. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: A double-blind placebo-controlled trial, followed by an open-label extension. Eur. Psychiatry 2012 27 5 335 342 10.1016/j.eurpsy.2011.05.004 21807480
    [Google Scholar]
  81. Barceló-Coblijn G. Murphy E.J. Alpha-linolenic acid and its conversion to longer chain n−3 fatty acids: Benefits for human health and a role in maintaining tissue n−3 fatty acid levels. Prog. Lipid Res. 2009 48 6 355 374 10.1016/j.plipres.2009.07.002 19619583
    [Google Scholar]
  82. Burdge G.C. Wootton S.A. Conversion of α-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br. J. Nutr. 2002 88 4 411 420 10.1079/BJN2002689 12323090
    [Google Scholar]
  83. Scoglio S. Canestrari F. Benedetti S. Benedetti Y. Delgado-Esteban M. Alphanizomenon flos aquae preparation, extracts and purified components thereof for the treatment of neurological, neurodegenerative and mood disorders. US Patent 9522167B2 2007
  84. Scoglio S. Benedetti Y. Benvenuti F. Battistelli S. Canestrari F. Benedetti S. Selective monoamine oxidase B inhibition by an Aphanizomenon flos-aquae extract and by its constitutive active principles phycocyanin and mycosporine-like amino acids. Phytomedicine 2014 21 7 992 997 10.1016/j.phymed.2014.03.006 24690316
    [Google Scholar]
  85. Satoi M. Matsuishi T. Yamada S. Yamashita Y. Ohtaki E. Mori K. Riikonen R. Kato H. Percy A.K. Decreased cerebrospinal fluid levels of? -phenylethylamine in patients with Rett syndrome. Ann. Neurol. 2000 47 6 801 803 10.1002/1531‑8249(200006)47:6<801::AID‑ANA13>3.0.CO;2‑L 10852546
    [Google Scholar]
  86. Kusaga A. Yamashita Y. Koeda T. Hiratani M. Kaneko M. Yamada S. Matsuishi T. Increased urine phenylethylamine after methylphenidate treatment in children with ADHD. Ann. Neurol. 2002 52 3 372 374 10.1002/ana.10302 12205654
    [Google Scholar]
  87. Matsuishi T. Yamashita Y. Neurochemical and neurotransmitter studies in patients with learning disabilities. No To Hattatsu 1999 31 3 245 248 10355264
    [Google Scholar]
  88. Irsfeld M. Spadafore M. Prüß B.M. β-phenylethylamine, a small molecule with a large impact. Webmedcentral 2013 4 9 4409 24482732
    [Google Scholar]
  89. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 1999 56 12 1073 1086 10.1001/archpsyc.56.12.1073 10591283
    [Google Scholar]
  90. Cremonte M. Sisti D. Maraucci I. Giribone S. Colombo E. Rocchi M.B.L. Scoglio S. The Effect of experimental supplementation with the Klamath algae extract Klamin on attention-deficit/hyperactivity disorder. J. Med. Food 2017 20 12 1233 1239 10.1089/jmf.2016.0181 29116873
    [Google Scholar]
  91. Wells M.L. Potin P. Craigie J.S. Raven J.A. Merchant S.S. Helliwell K.E. Smith A.G. Camire M.E. Brawley S.H. Algae as nutritional and functional food sources: revisiting our understanding. J. Appl. Phycol. 2017 29 2 949 982 10.1007/s10811‑016‑0974‑5 28458464
    [Google Scholar]
  92. Ratledge C. Microbial oils: an introductory overview of current status and future prospects. Oilseeds Fats Crops Lipids 2013 20 6 D602 10.1051/ocl/2013029
    [Google Scholar]
  93. Deckelbaum R.J. Torrejon C. The omega-3 fatty acid nutritional landscape: Health benefits and sources. J. Nutr. 2012 142 3 587S 591S 10.3945/jn.111.148080 22323763
    [Google Scholar]
  94. Deckelbaum R.J. Calder P.C. Editorial: Is it time to separate EPA from DHA when using omega-3 fatty acids to protect heart and brain? Curr. Opin. Clin. Nutr. Metab. Care 2020 23 2 65 67 10.1097/MCO.0000000000000632 32028319
    [Google Scholar]
  95. Castro L.F.C. Tocher D.R. Monroig O. Long-chain polyunsaturated fatty acid biosynthesis in chordates: Insights into the evolution of Fads and Elovl gene repertoire. Prog. Lipid Res. 2016 62 25 40 10.1016/j.plipres.2016.01.001 26769304
    [Google Scholar]
  96. Tocher D.R. Omega-3 long-chain polyunsaturated fatty acids and aquaculture in perspective. Aquaculture 2015 449 94 107 10.1016/j.aquaculture.2015.01.010
    [Google Scholar]
  97. Fabris M. Abbriano R.M. Pernice M. Sutherland D.L. Commault A.S. Hall C.C. Labeeuw L. McCauley J.I. Kuzhiuparambil U. Ray P. Kahlke T. Ralph P.J. Emerging technologies in algal biotechnology: Toward the establishment of a sustainable, algae-based bioeconomy. Front. Plant Sci. 2020 11 279 10.3389/fpls.2020.00279 32256509
    [Google Scholar]
  98. Tocher D. Betancor M. Sprague M. Olsen R. Napier J. Omega-3 long-chain polyunsaturated fatty acids, EPA and DHA: Bridging the gap between supply and demand. Nutrients 2019 11 1 89 10.3390/nu11010089 30621155
    [Google Scholar]
  99. Jovanovic S. Dietrich D. Becker J. Kohlstedt M. Wittmann C. Microbial production of polyunsaturated fatty acids — high-value ingredients for aquafeed, superfoods, and pharmaceuticals. Curr. Opin. Biotechnol. 2021 69 199 211 10.1016/j.copbio.2021.01.009 33540327
    [Google Scholar]
  100. Lu Q. Li H. Xiao Y. Liu H. A state-of-the-art review on the synthetic mechanisms, production technologies, and practical application of polyunsaturated fatty acids from microalgae. Algal Res. 2021 55 102281 10.1016/j.algal.2021.102281
    [Google Scholar]
  101. Ochsenreither K. Glück C. Stressler T. Fischer L. Syldatk C. Production strategies and applications of microbial single cell oils. Front. Microbiol. 2016 7 1539 10.3389/fmicb.2016.01539 27761130
    [Google Scholar]
  102. Lauritzen L. Hansen H.S. Jørgensen M.H. Michaelsen K.F. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog. Lipid Res. 2001 40 1-2 1 94 10.1016/S0163‑7827(00)00017‑5 11137568
    [Google Scholar]
  103. Birch E.E. Birch D.G. Hoffman D.R. Uauy R. Dietary essential fatty acid supply and visual acuity development. Invest. Ophthalmol. Vis. Sci. 1992 33 11 3242 3253 1399429
    [Google Scholar]
  104. Carlson S.E. Ford A.J. Werkman S.H. Peeples J.M. Koo W.W.K. Visual acuity and fatty acid status of term infants fed human milk and formulas with and without docosahexaenoate and arachidonate from egg yolk lecithin. Pediatr. Res. 1996 39 5 882 888 10.1203/00006450‑199605000‑00024 8726246
    [Google Scholar]
  105. Jasani B. Simmer K. Patole S.K. Rao S.C. Long chain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Libr. 2017 2017 3 CD000376 10.1002/14651858.CD000376.pub4 28281303
    [Google Scholar]
  106. Schulzke S.M. Patole S.K. Simmer K. Long-chain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database Syst. Rev. 2011 2 2 CD000375 10.1002/14651858.CD000375.pub4 21328248
    [Google Scholar]
  107. Gould J.F. Smithers L.G. Makrides M. The effect of maternal omega-3 (n-3) LCPUFA supplementation during pregnancy on early childhood cognitive and visual development: a systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2013 97 3 531 544 10.3945/ajcn.112.045781 23364006
    [Google Scholar]
  108. Cooper R.E. Tye C. Kuntsi J. Vassos E. Asherson P. The effect of omega-3 polyunsaturated fatty acid supplementation on emotional dysregulation, oppositional behaviour and conduct problems in ADHD: A systematic review and meta-analysis. J. Affect. Disord. 2016 190 474 482 10.1016/j.jad.2015.09.053 26551407
    [Google Scholar]
  109. Chang J.P.C. Su K.P. Mondelli V. Pariante C.M. Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: A systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacology 2018 43 3 534 545 10.1038/npp.2017.160 28741625
    [Google Scholar]
  110. Derbyshire E. Omega-3/6 fatty acids have a therapeutic role in children and young people with ADHD? J. Lipids 2017 2017 1 9 10.1155/2017/6285218 28951787
    [Google Scholar]
  111. Richardson A.J. Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukot. Essent. Fatty Acids 2004 70 4 383 390 10.1016/j.plefa.2003.12.020 15041031
    [Google Scholar]
  112. Yui K. Koshiba M. Nakamura S. Kobayashi Y. Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: A double-blind, placebo-controlled, randomized trial. J. Clin. Psychopharmacol. 2012 32 2 200 206 10.1097/JCP.0b013e3182485791 22370992
    [Google Scholar]
  113. Milte C.M. Parletta N. Buckley J.D. Coates A.M. Young R.M. Howe P.R.C. Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: A randomized controlled trial. Nutrition 2012 28 6 670 677 10.1016/j.nut.2011.12.009 22541055
    [Google Scholar]
  114. Gustafsson P.A. Birberg-Thornberg U. Duchén K. Landgren M. Malmberg K. Pelling H. Strandvik B. Karlsson T. EPA supplementation improves teacher‐rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr. 2010 99 10 1540 1549 10.1111/j.1651‑2227.2010.01871.x 20491709
    [Google Scholar]
  115. Bos D.J. Oranje B. Veerhoek E.S. Van Diepen R.M. Weusten J.M.H. Demmelmair H. Koletzko B. de Sain-van der Velden M.G.M. Eilander A. Hoeksma M. Durston S. Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacology 2015 40 10 2298 2306 10.1038/npp.2015.73 25790022
    [Google Scholar]
  116. Yurko-Mauro K. Alexander D.D. Van Elswyk M.E. Docosahexaenoic acid and adult memory: A systematic review and meta-analysis. PLoS One 2015 10 3 e0120391 10.1371/journal.pone.0120391 25786262
    [Google Scholar]
  117. van de Rest O. Geleijnse J.M. Kok F.J. van Staveren W.A. Dullemeijer C. OldeRikkert M.G.M. Beekman A.T.F. de Groot C.P.G.M. Effect of fish oil on cognitive performance in older subjects. Neurology 2008 71 6 430 438 10.1212/01.wnl.0000324268.45138.86 18678826
    [Google Scholar]
  118. Sydenham E. Dangour A.D. Lim W.S. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Libr. 2012 2012 9 CD005379 10.1002/14651858.CD005379.pub3 22696350
    [Google Scholar]
  119. Dangour A.D. Allen E. Elbourne D. Fasey N. Fletcher A.E. Hardy P. Holder G.E. Knight R. Letley L. Richards M. Uauy R. Effect of 2-y n−3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am. J. Clin. Nutr. 2010 91 6 1725 1732 10.3945/ajcn.2009.29121 20410089
    [Google Scholar]
  120. Yurko-Mauro K. McCarthy D. Rom D. Nelson E.B. Ryan A.S. Blackwell A. Salem N. Stedman M. Beneficial effects of docosahexaenoic acid on cognition in age‐related cognitive decline. Alzheimers Dement. 2010 6 6 456 464 10.1016/j.jalz.2010.01.013 20434961
    [Google Scholar]
  121. Geleijnse J.M. Giltay E.J. Kromhout D. Effects of n‐3 fatty acids on cognitive decline: A randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimers Dement. 2012 8 4 278 287 10.1016/j.jalz.2011.06.002 21967845
    [Google Scholar]
  122. Rogers P.J. Appleton K.M. Kessler D. Peters T.J. Gunnell D. Hayward R.C. Heatherley S.V. Christian L.M. McNaughton S.A. Ness A.R. No effect of n -3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: A randomised controlled trial. Br. J. Nutr. 2008 99 2 421 431 10.1017/S0007114507801097 17956647
    [Google Scholar]
  123. Bowman G.L. Silbert L.C. Dodge H.H. Hagen K. David J.C. Murchison C.F. Lahna D. Kaye J. Quinn J.F. Shinto L. Effects of omega‐3 fatty acids on cerebral white matter hyperintensities and medial temporal lobe atrophy in older non‐demented adults: A 3‐year randomized‐controlled phase 2 trial. Alzheimers Dement. 2020 16 S10 e046608 10.1002/alz.046608
    [Google Scholar]
  124. Levy R. Hadad N. Sedlov T. Zelkha M. Sapojnik M. Anti-inflammatory omega-3 synergistic combinations. US Patent 9901562B2 2018
  125. Andrieu S. Guyonnet S. Coley N. Cantet C. Bonnefoy M. Bordes S. Bories L. Cufi M.N. Dantoine T. Dartigues J.F. Desclaux F. Gabelle A. Gasnier Y. Pesce A. Sudres K. Touchon J. Robert P. Rouaud O. Legrand P. Payoux P. Caubere J.P. Weiner M. Carrié I. Ousset P.J. Vellas B. Vellas B. Guyonnet S. Carrié I. Brigitte L. Faisant C. Lala F. Delrieu J. Villars H. Combrouze E. Badufle C. Zueras A. Andrieu S. Cantet C. Morin C. Van Kan G.A. Dupuy C. Rolland Y. Caillaud C. Ousset P-J. Fougère B. Willis S. Belleville S. Gilbert B. Fontaine F. Dartigues J-F. Marcet I. Delva F. Foubert A. Cerda S. Noëlle-Cuffi M. Costes C. Rouaud O. Manckoundia P. Quipourt V. Marilier S. Franon E. Bories L. Pader M-L. Basset M-F. Lapoujade B. Faure V. Li M. Tong Y. Malick-Loiseau C. Cazaban-Campistron E. Desclaux F. Blatge C. Dantoine T. Laubarie-Mouret C. Saulnier I. Clément J-P. Picat M-A. Bernard-Bourzeix L. Willebois S. Désormais I. Cardinaud N. Bonnefoy M. Livet P. Rebaudet P. Gédéon C. Burdet C. Terracol F. Pesce A. Roth S. Chaillou S. Louchart S. Sudres K. Lebrun N. Barro-Belaygues N. Touchon J. Bennys K. Gabelle A. Romano A. Touati L. Marelli C. Pays C. Robert P. Le Duff F. Gervais C. Gonfrier S. Gasnier Y. Bordes S. Begorre D. Carpuat C. Khales K. Lefebvre J-F. El Idrissi S.M. Skolil P. Salles J-P. Dufouil C. Lehéricy S. Chupin M. Mangin J-F. Bouhayia A. Allard M. Ricolfi F. Dubois D. Paule M. Martel B. Cotton F. Bonafé A. Chanalet S. Hugon F. Bonneville F. Cognard C. Chollet F. Payoux P. Voisin T. Peiffer S. Hitzel A. Allard M. Zanca M. Monteil J. Darcourt J. Molinier L. Derumeaux H. Costa N. Vincent C. Perret B. Vinel C. Olivier-Abbal P. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): A randomised, placebo-controlled trial. Lancet Neurol. 2017 16 5 377 389 10.1016/S1474‑4422(17)30040‑6 28359749
    [Google Scholar]
  126. Delrieu J.V. Cantet C. Bateman R. Andrieu S. Multidomain intervention and/or omega-3 in non-domented subjects according to plasma Ab42/40 ratio: Cognitive impact at 3 and 5 years in a subgroup analysis from the randomized clinical MAPT trial. J. Prev. Alzheimers Dis. 2020 7 s48 s49 10.1186/s13195‑023‑01325‑3 37872582
    [Google Scholar]
  127. Soininen H. Solomon A. Visser P.J. Hendrix S.B. Blennow K. Kivipelto M. Hartmann T. 36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer’s disease. Alzheimers Dement. 2021 17 1 29 40 10.1002/alz.12172 32920957
    [Google Scholar]
  128. Soininen H. Solomon A. Visser P.J. Hendrix S.B. Blennow K. Kivipelto M. Hartmann T. Hallikainen I. Hallikainen M. Helisalmi S. Lappalainen T. Liu Y. Paajanen T. Wahlund L-O. Freund-Levi Y. Andreasen N. Hagman G. Lindblom S. Fassbender K. Riemenschneider M. Grimm M.O.W. Klees-Rollmann A. Luley M. Lyros E. Schomburg R. Kennel J. Ramelli D. Frölich L. Hausner L. Laske C. Leyhe T. Mychajliw C. Koehler N. Schiekofer S. Klünemann H. Schröder J. Lütjohann D. Scheltens P. van Rossum I. Scheltens N. Bertens D. ten Kate M. Barkhof F. Henselmans J.M.L. Roks G. van Hees A.M.J. Ellison N. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): A randomised, double-blind, controlled trial. Lancet Neurol. 2017 16 12 965 975 10.1016/S1474‑4422(17)30332‑0 29097166
    [Google Scholar]
  129. Fortier M. Castellano C.A. Croteau E. Langlois F. Bocti C. St-Pierre V. Vandenberghe C. Bernier M. Roy M. Descoteaux M. Whittingstall K. Lepage M. Turcotte É.E. Fulop T. Cunnane S.C. A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment. Alzheimers Dement. 2019 15 5 625 634 10.1016/j.jalz.2018.12.017 31027873
    [Google Scholar]
  130. Abidizadegan M. Blomster J. Fewer D. Peltomaa E. Promising biomolecules with high antioxidant capacity derived from cryptophyte algae grown under different light conditions. Biology 2022 11 8 1112 10.3390/biology11081112 35892969
    [Google Scholar]
  131. Raja R. Hemaiswarya S. Kumar N.A. Sridhar S. Rengasamy R. A perspective on the biotechnological potential of microalgae. Crit. Rev. Microbiol. 2008 34 2 77 88 10.1080/10408410802086783 18568862
    [Google Scholar]
  132. Sathasivam R. Radhakrishnan R. Hashem A. Abd Allah E.F. Microalgae metabolites: A rich source for food and medicine. Saudi J. Biol. Sci. 2019 26 4 709 722 10.1016/j.sjbs.2017.11.003 31048995
    [Google Scholar]
  133. Cheng K.C. Ogden K.L. Algal biofuels. Chem. Eng. Prog. 2011 107 42 47 10.1016/j.cej.2011.07.033
    [Google Scholar]
  134. In C.B.L. Freshwater algae of North America: Ecology and classification. USA Academic Press 2015
    [Google Scholar]
  135. Greenwold MJ Cunningham BR Lachenmyer EM Pullman JM Richardson TL Dudycha JL Diversification of light capture ability was accompanied by the evolution of phycobiliproteins in cryptophyte algae. Proc Biol Sci 2019 286 1902 20190655 10.1098/rspb.2019.0655 31088271
    [Google Scholar]
  136. Jubie S. Ramesh P.N. Dhanabal P. Kalirajan R. Muruganantham N. Shanish Antony A. Synthesis, antidepressant and antimicrobial activities of some novel stearic acid analogues. Eur. J. Med. Chem. 2012 54 931 935 10.1016/j.ejmech.2012.06.025 22770606
    [Google Scholar]
  137. Calder P.C. Very long-chain n -3 fatty acids and human health: fact, fiction and the future. Proc. Nutr. Soc. 2018 77 1 52 72 10.1017/S0029665117003950 29039280
    [Google Scholar]
  138. Pawełczyk T. Trafalska E. Kotlicka-Antczak M. Pawełczyk A. The association between polyunsaturated fatty acid consumption and the transition to psychosis in ultra-high risk individuals. Prostaglandins Leukot. Essent. Fatty Acids 2016 108 30 37 10.1016/j.plefa.2016.03.010 27154362
    [Google Scholar]
  139. Abidizadegan M. Peltomaa E. Blomster J. The potential of cryptophyte algae in biomedical and pharmaceutical applications. Front. Pharmacol. 2021 11 618836 10.3389/fphar.2020.618836 33603668
    [Google Scholar]
  140. Ghosh T. Paliwal C. Maurya R. Mishra S. Microalgal rainbow colours for nutraceutical and pharmaceutical applications. Plant diversity, organization, function and improvement. New Delhi, India Springer Bahadur B. Venkat Rajam M.V. Sahijram L. Krishnamurthy K.V. 2015 777 791 10.1007/978‑81‑322‑2286‑6_32
    [Google Scholar]
  141. Coronado-Reyes J.A. Salazar-Torres J.A. Juárez-Campos B. González-Hernández J.C. Chlorella vulgaris, a microalgae important to be used in Biotechnology: A review. Food Sci. Technol. 2022 42 e37320 10.1590/fst.37320
    [Google Scholar]
  142. Cuellar-Bermudez S.P. Aguilar-Hernandez I. Cardenas-Chavez D.L. Ornelas-Soto N. Romero-Ogawa M.A. Parra-Saldivar R. Extraction and purification of high‐value metabolites from microalgae: Essential lipids, astaxanthin and phycobiliproteins. Microb. Biotechnol. 2015 8 2 190 209 10.1111/1751‑7915.12167 25223877
    [Google Scholar]
  143. Ward O.P. Singh A. Omega-3/6 fatty acids: Alternative sources of production. Process Biochem. 2005 40 12 3627 3652 10.1016/j.procbio.2005.02.020
    [Google Scholar]
  144. Barreira L. Pereira H. Gangadhar K.N. Custódio L. Varela J. Medicinal effects of microalgae-derived fatty acids. Handbook of Marine Microlage Amsterdam, Netherlands Elsevier Kim S.K. 2015 209 231 10.1016/B978‑0‑12‑800776‑1.00013‑3
    [Google Scholar]
  145. Patil V. Källqvist T. Olsen E. Vogt G. Gislerød H.R. Fatty acid composition of 12 microalgae for possible use in aquaculture feed. Aquacult. Int. 2007 15 1 1 9 10.1007/s10499‑006‑9060‑3
    [Google Scholar]
  146. Peltomaa E. Johnson M. Taipale S. Marine cryptophytes are great sources of EPA and DHA. Mar. Drugs 2017 16 1 3 10.3390/md16010003 29278384
    [Google Scholar]
  147. Huerlimann R. de Nys R. Heimann K. Growth, lipid content, productivity, and fatty acid composition of tropical microalgae for scale‐up production. Biotechnol. Bioeng. 2010 107 2 245 257 10.1002/bit.22809 20506156
    [Google Scholar]
  148. Bleakley S. Hayes M. Algal Proteins: Extraction, Application, and Challenges Concerning Production. Foods 2017 6 5 33 10.3390/foods6050033 28445408
    [Google Scholar]
  149. Ryu B. Qian Z.J. Kim S.K. Purification of a peptide from seahorse, that inhibits TPA-induced MMP, iNOS and COX-2 expression through MAPK and NF-κB activation, and induces human osteoblastic and chondrocytic differentiation. Chem. Biol. Interact. 2010 184 3 413 422 10.1016/j.cbi.2009.12.003 20004183
    [Google Scholar]
  150. Macedo M.W.F.S. Cunha N.B. Carneiro J.A. Costa R.A. Alencar S.A. Cardoso M.H. Franco O.L. Dias S.C. Marine organisms as a rich source of biologically active peptides. Front. Mar. Sci. 2021 8 667764 10.3389/fmars.2021.667764
    [Google Scholar]
  151. Shahidi F. Zhong Y. Bioactive peptides. J. AOAC Int. 2008 91 4 914 931 10.1093/jaoac/91.4.914 18727554
    [Google Scholar]
  152. Chiba T. Nishimoto I. Aiso S. Matsuoka M. Neuroprotection against neurodegenerative diseases. Mol. Neurobiol. 2007 35 1 55 84 10.1007/BF02700624 17519506
    [Google Scholar]
  153. Dejda A. Sokołowska P. Nowak J.Z. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol. Rep. 2005 57 3 307 320 15985713
    [Google Scholar]
  154. Ahn J. Ahn H.S. Cheong J.H. dela Peña I. Natural product‐derived treatments for attention‐deficit/hyperactivity disorder: Safety, efficacy, and therapeutic potential of combination therapy. Neural Plast. 2016 2016 1 1 18 10.1155/2016/1320423 26966583
    [Google Scholar]
  155. Rosi E. Grazioli S. Villa F.M. Mauri M. Gazzola E. Pozzi M. Molteni M. Nobile M. Use of non-pharmacological supplementations in children and adolescents with attention deficit/hyperactivity disorder: A critical review. Nutrients 2020 12 6 1573 10.3390/nu12061573 32481502
    [Google Scholar]
  156. Ghoubadzadeh S Pasha R Bakhtiarpoor S Homaei R. The effects of cognitive-emotional skills training on impulsivity symptoms, attention, and concentration in students with attention-deficit/hyperactivity disorder. J. Disabil. Stud. 2021 11
    [Google Scholar]
  157. Hao Z.W. Zhang Z.Y. Wang Z.P. Wang Y. Chen J.Y. Chen T.H. Shi G. Li H.K. Wang J.W. Dong M.C. Hong L. Li J.F. Bioactive peptides and proteins for tissue repair: microenvironment modulation, rational delivery, and clinical potential. Mil. Med. Res. 2024 11 1 75 10.1186/s40779‑024‑00576‑x 39639374
    [Google Scholar]
  158. Roh M.K. Uddin M.S. Chun B.S. Extraction of fucoxanthin and polyphenol from Undaria pinnatifida using supercritical carbon dioxide with co-solvent. Biotechnol. Bioprocess Eng.; BBE 2008 13 6 724 729 10.1007/s12257‑008‑0104‑6
    [Google Scholar]
  159. Shang Y.F. Kim S.M. Lee W.J. Um B.H. Pressurized liquid method for fucoxanthin extraction from Eisenia bicyclis (Kjellman) Setchell. J. Biosci. Bioeng. 2011 111 2 237 241 10.1016/j.jbiosc.2010.10.008 21081286
    [Google Scholar]
  160. Kim S.M. Shang Y.F. Um B.H. A preparative method for isolation of fucoxanthin from Eisenia bicyclis by centrifugal partition chromatography. Phytochem. Anal. 2011 22 4 322 329 10.1002/pca.1283 21337648
    [Google Scholar]
  161. Delgado-Vargas F. Jiménez A.R. Paredes-López O. Natural pigments: Carotenoids, anthocyanins, and betalains--characteristics, biosynthesis, processing, and stability. Crit. Rev. Food Sci. Nutr. 2000 40 3 173 289 10.1080/10408690091189257 10850526
    [Google Scholar]
  162. Khan S.B. Kong C.S. Kim J.A. Kim S.K. Protective effect of Amphiroa dilatata on ROS induced oxidative damage and MMP expressions in HT1080 cells. Biotechnol. Bioprocess Eng.; BBE 2010 15 1 191 198 10.1007/s12257‑009‑0052‑9
    [Google Scholar]
  163. Kumar P. Yadav N. Chaudhary B. Jain V. Balaramnavar V.M. Alharbi K.S. Alenezi S.K. Al-Malki W.H. Ghoneim M.M. Alshehri S. Imam S.S. Gupta M.M. Promises of phytochemical based nano drug delivery systems in the management of cancer. Chem. Biol. Interact. 2022 351 109745 10.1016/j.cbi.2021.109745 34774839
    [Google Scholar]
  164. Ikeda K. Kitamura A. Machida H. Watanabe M. Negishi H. Hiraoka J. Nakano T. Effect of Undaria pinnatifida (Wakame) on the development of cerebrovascular diseases in stroke‐prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 2003 30 1-2 44 48 10.1046/j.1440‑1681.2003.03786.x 12542452
    [Google Scholar]
  165. Khodosevich K. Monyer H. Signaling involved in neurite outgrowth of postnatally born subventricular zone neurons in vitro. BMC Neurosci. 2010 11 1 18 10.1186/1471‑2202‑11‑18 20146799
    [Google Scholar]
  166. Ina A. Hayashi K.I. Nozaki H. Kamei Y. Pheophytin a, a low molecular weight compound found in the marine brown alga Sargassum fulvellum, promotes the differentiation of PC12 cells. Int. J. Dev. Neurosci. 2007 25 1 63 68 10.1016/j.ijdevneu.2006.09.323 17092682
    [Google Scholar]
  167. Ina A. Kamei Y. Vitamin B12, a chlorophyll-related analog to pheophytin a from marine brown algae, promotes neurite outgrowth and stimulates differentiation in PC12 cells. Cytotechnology 2006 52 3 181 187 10.1007/s10616‑006‑9038‑z 19002876
    [Google Scholar]
  168. Mohd Sairazi N.S. Sirajudeen K.N.S. Natural products and their bioactive compounds: Neuroprotective potentials against neurodegenerative diseases. Evid. Based Complement. Alternat. Med. 2020 2020 1 6565396 10.1155/2020/6565396 32148547
    [Google Scholar]
  169. Batool Z. Chen J.H. Gao Y. Lu L.W. Xu H. Liu B. Wang M. Chen F. Natural carotenoids as neuroprotective agents for Alzheimer’s disease: An evidence-based comprehensive review. J. Agric. Food Chem. 2022 70 50 15631 15646 10.1021/acs.jafc.2c06206 36480951
    [Google Scholar]
  170. Liu Y. Renaissance of marine natural product drug discovery and development. J. Mar. Sci. Res. Dev. 2012 2 2 2 10.4172/2155‑9910.1000e106
    [Google Scholar]
  171. Händel M.N. Rohde J.F. Rimestad M.L. Bandak E. Birkefoss K. Tendal B. Lemcke S. Callesen H.E. Efficacy and safety of polyunsaturated fatty acids supplementation in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents: A systematic review and meta-analysis of clinical trials. Nutrients 2021 13 4 1226 10.3390/nu13041226 33917727
    [Google Scholar]
  172. Martins A. Conte M. Goettert M.I. Contini V. Attention-deficit/hyperactivity disorder and inflammation: Natural product-derived treatments - A review of the last ten years. Inflammopharmacology 2023 31 6 2939 2954 10.1007/s10787‑023‑01339‑1 37740887
    [Google Scholar]
  173. Barbalace M.C. Malaguti M. Giusti L. Lucacchini A. Hrelia S. Angeloni C. Anti-inflammatory activities of marine algae in neurodegenerative diseases. Int. J. Mol. Sci. 2019 20 12 3061 10.3390/ijms20123061 31234555
    [Google Scholar]
  174. Kumar S Saha S Singh K Singh T Mishra AK Dubey BN Singh S Beneficial effects of spirulina on brain health: A systematic review. Curr. Funct. Foods 2025 3 1 E120124225622 10.2174/0126668629269256231222092721
    [Google Scholar]
  175. Corona J.C. Role of oxidative stress and neuroinflammation in attention-deficit/hyperactivity disorder. Antioxidants 2020 9 11 1039 10.3390/antiox9111039 33114154
    [Google Scholar]
  176. PDC-1421 treatment in adult patients with ADHD. NCT05202327. 2022 US National Library of Medicine Available from: https://clinicaltrials.gov/ct2/show/NCT05202327
    [Google Scholar]
  177. Wigal S.B. Wigal T. Hobart M. Madera J.J. Baker R.A. Kohegyi E. McKinney A. Wilens T.E. Safety and efficacy of centanafadine sustained-release in adults with attention-deficit hyperactivity disorder: Results of phase 2 studies. Neuropsychiatr. Dis. Treat. 2020 16 1411 1426 10.2147/NDT.S242084 32606695
    [Google Scholar]
  178. Adler L.A. Adams J. Madera-McDonough J. Kohegyi E. Hobart M. Chang D. Angelicola M. McQuade R. Liebowitz M. Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder: Results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials. J. Clin. Psychopharmacol. 2022 42 5 429 439 10.1097/JCP.0000000000001575 35652746
    [Google Scholar]
  179. Hashimoto K. Sasaki T. Old drug tipepidine as new hope for children with ADHD. Aust. N. Z. J. Psychiatry 2015 49 2 181 182 10.1177/0004867414553952 25280911
    [Google Scholar]
  180. Dasotraline. IUPHAR/BPS Guide to Pharmacology 2022 Available from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8308
    [Google Scholar]
  181. Vandana P. Arnold E. Dasotraline in ADHD: Novel or me too drug? Expert Rev. Neurother. 2019 19 4 311 315 10.1080/14737175.2019.1593826 30871381
    [Google Scholar]
  182. Sunovion discontinues dasotraline program. 2020 Available from: https://news.sunovion.com/press-releases/press-releases-details/2020/Sunovion-Discontinues-Dasotraline-Program/default.aspx
  183. Vallon Pharmaceuticals continues advancement of pivotal study in lead development program ADAIR toward potential approval. 2021 Available from: https://www.vallon-pharma.com/news/vallon-pharmaceuticals-continues-advancement-of-pivotal-study-in-lead-development-program-adair-toward-potential-approval/
  184. Vallon pharmaceuticals reports additional pharmacokinetic and pharmacodynamic data from SEAL study of ADAIR. 2022 Available from: https://www.vallon-pharma.com/news/vallon-pharmaceuticals-reports-additional-pharmacokinetic-and-pharmacodynamic-data-from-seal-study-of-adair/
  185. A study of PDC-1421 treatment in adult patients with attention-deficit hyperactivity disorder (ADHD). NCT02699086. 2021 Available from: https://clinicaltrials.gov/ct2/show/NCT02699086
  186. Nasir M. Bloch M.H. Trim the fat: The role of omega-3 fatty acids in psychopharmacology. Ther. Adv. Psychopharmacol. 2019 9 2045125319869791 10.1177/2045125319869791 31489174
    [Google Scholar]
  187. Kean J.D. Sarris J. Scholey A. Silberstein R. Downey L.A. Stough C. Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): A randomised, double-blind, placebo-controlled trial. Psychopharmacology 2017 234 3 403 420 10.1007/s00213‑016‑4471‑y 27921139
    [Google Scholar]
  188. Bloch M.H. Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: Systematic review and meta-analysis. J. Am. Acad. Child Adolesc. Psychiatry 2011 50 10 991 1000 10.1016/j.jaac.2011.06.008 21961774
    [Google Scholar]
  189. Al-Ghannami S.S. Al-Adawi S. Ghebremeskel K. Hussein I.S. Min Y. Jeyaseelan L. Al-Shammakhi S.M. Mabry R.M. Al-Oufi H.S. Randomized open-label trial of docosahexaenoic acid–enriched fish oil and fish meal on cognitive and behavioral functioning in Omani children. Nutrition 2019 57 167 172 10.1016/j.nut.2018.04.008 30195244
    [Google Scholar]
  190. Ngo D.H. Wijesekara I. Vo T.S. Van Ta Q. Kim S.K. Marine food-derived functional ingredients as potential antioxidants in the food industry: An overview. Food Res. Int. 2011 44 2 523 529 10.1016/j.foodres.2010.12.030
    [Google Scholar]
  191. Zebua RD Waruwu E Telaumbanua BV Laoli D Potential for developing phytopharmacy based on marine resources: Review. Asian J. Aquat. Sci. 2023 6 3 352 360 10.31258/ajoas.6.3.352‑360
    [Google Scholar]
/content/journals/cnsnddt/10.2174/0118715273418458251114104948
Loading
Neuroprotective Marine Bioactives in Paediatric ADHD: A Focused Review on Therapeutic Potential
Bentham Science Publishers ; https://doi.org/10.2174/0118715273418458251114104948
/content/journals/cnsnddt/10.2174/0118715273418458251114104948
/content/journals/cnsnddt/10.2174/0118715273418458251114104948
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: hyperactivity disorder ; anti-inflammatory ; neuroregenerative properties ; antioxidant ; attention-deficit disorder ; marine bioactives ; Neuroprotection

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test